Narzahni Crumbie, APRN
Family · Oro Valley, AZNPI 1821554999
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,140 of the $22,303 with a category attached, or 63.4%. Phathom Pharmaceuticals, Inc. accounts for 79.1% of it on its own, with 22 other manufacturers making up the rest. Reporting peaked in 2024 at $15,114 and has fallen 58.1% since, to $6,329 in 2025. Among family clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 342 payments — averaging $65.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$18K
- AbbVie$999
- Johnson & Johnson$701
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$581
- Madrigal Pharmaceuticals$368
- Takeda Pharmaceuticals U.S.A., Inc.$332
- plus $2K from 17 others
What the payments were for
- Speaking & faculty fees$14,14063%
- Travel & lodging$2,23510%
- Food & beverage$5,86126%
- Education$670%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 101 | $17,642 |
| AbbVie | 49 | $999 |
| Johnson & Johnson(2 entities) | 36 | $701 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 47 | $581 |
| Madrigal Pharmaceuticals | 4 | $368 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $332 |
| Sanofi | 14 | $277 |
| Pfizer | 16 | $252 |
| Regeneron Healthcare Solutions, Inc. | 8 | $229 |
| Ardelyx, Inc. | 7 | $203 |
| Novo Nordisk | 2 | $136 |
| Aimmune Therapeutics, Inc. | 17 | $136 |
| Intercept Pharmaceuticals, Inc. | 5 | $102 |
| Lilly USA, LLC | 4 | $73 |
| Ipsen Biopharmaceuticals, Inc | 3 | $71 |
| Bristol Myers Squibb | 3 | $45 |
| Sandoz | 2 | $42 |
| Mylan Institutional Inc. | 1 | $23 |
| Merck | 1 | $21 |
| Organon | 1 | $20 |
| Gilead | 1 | $20 |
| Digestive Care, Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,303 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 31 | $129,625 |
| CreonLipase/Protease/Amylase | 41 | $121,433 |
| Dupixent PenDupilumab | 15 | $105,420 |
| Humira(Cf) PenAdalimumab | 12 | $96,695 |
| XifaxanRifaximin | 17 | $48,496 |
| LinzessLinaclotide | 66 | $45,918 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 143 | $23,497 |
| TrulancePlecanatide | 13 | $12,823 |
| Mesalamine | 19 | $12,089 |
| Sucralfate | 36 | $3,272 |
| Esomeprazole Magnesium | 34 | $2,824 |
| Pantoprazole Sodium | 210 | $2,581 |
| Dexlansoprazole DrDexlansoprazole | 13 | $2,034 |
| Budesonide DrBudesonide | 18 | $1,818 |
| Omeprazole | 118 | $1,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $999 | $167,351107 claims |
| Aimmune Therapeutics, Inc.Zenpep | $136 | $129,62531 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $581 | $61,31930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.
Other family in Oro Valley
- Sharon MagalonaMesa$441K
- Angela GoldenMunds Park$378K
- Kimberly HallaPhoenix$332K
- Kaitlyn LouchheimScottsdale$208K
- Rebecca McCollaumMesa$149K
- Lindsay CarterTucson$108K
- Audrey StevensonPhoenix$83K
- Celeste FineGilbert$82K
- Mia ChorneyChandler$79K
- Jennifer PrinceScottsdale$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.